Isconova AB - Uppsala

Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.